News

Holding(s) in Company
Holding(s) in Company
January 18, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 15 January 2021.

Director/PDMR Shareholding
Director/PDMR Shareholding
September 15, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 14 September 2020 it purchased 363,037 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.96p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,826,194 Ordinary Shares, equivalent to 22.30% of Proteome Sciences' total issued share capital.

Appointment of Chief Executive Officer
Appointment of Chief Executive Officer
September 14, 2020

The Board of Proteome Sciences plc is pleased to announce that Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer and she will take up the position on September 15th, 2020. Dr Ian Pike remains a director of the Company as Chief Scientific Officer, having also fulfilled the role of Interim Chief Executive Officer until Dr Söhngen’s appointment.

Interim results for the six months ended 30 June 2020
Interim results for the six months ended 30 June 2020
August 10, 2020

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2020.

Holding(s) in Company
Holding(s) in Company
July 27, 2020

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 24 July 2020.

Director/PDMR Shareholding
Director/PDMR Shareholding
July 7, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 3 July 2020 it purchased 99,999 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.90p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,463,157 Ordinary Shares, equivalent to 22.18% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
July 2, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 30 June and 1 July 2020 it purchased 100,000 and 60,000 Ordinary Shares of 1p, respectively,  in the capital of the Company ("Ordinary Shares") at an average price of 3.95p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,363,158 Ordinary Shares, equivalent to 22.14% of Proteome Sciences' total issued share capital.

Shareholder Questions & Answers - AGM 26 June 2020
Shareholder Questions & Answers - AGM 26 June 2020
June 26, 2020

Shareholder Questions & Answers 26 June 2020.

The following questions were submitted by Shareholders prior to the Company’s AGM held at 11 am on 26 June in a closed session due to COVID-19 restrictions. They have been put into appropriate categories and similar questions amalgamated.

The Company has prepared a new presentation for shareholders
The Company has prepared a new presentation for shareholders
June 26, 2020

The Company has prepared a new presentation for shareholders.

 

Result of Annual General Meeting (AGM)
Result of Annual General Meeting (AGM)
June 26, 2020

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 11.00 a.m. today, all resolutions were duly passed.

The Company has prepared a new presentation for shareholders and a copy will be available on the Company’s website later today.